Trial Profile
A phase II study of combination of Bendamustine and Brentuximab in patients with refractory and/or relapsed Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2016 New trial record